Paul Sargos, Radiation Oncologist, Head of the radiation oncology department at Institut Bergonié shared a post on X:
“What is AUGMENTED radiotherapy in the management of localy advanced/High-risk PCa?
Dose-escalation on the prostate gland over 78 Gy (including whole-gland or focal, or use of extreme hypofractionation to increase BED) and/or increase in target volumes.
The addition of a boost within the prostate gland over 78 Gy halves the risk of biochemical recurrence at 5 years.
The addition of whole pelvic radiotherapy (WPRT) provides a 5-year disease-free survival reaching 89.5% at 5 years, with no significant increase in late severe toxicity.
Combined approaches result in 9-year prostate cancer specific survival ranging between 96.1% and 100%
PEACE 7 TRIAL to be started soon:
SOC +/- Darolutamide +/- SBRT boost …
Congrats to Jennifer Le Guévelou for this great paper.
“Augmented radiotherapy” in the management of high-risk prostate cancer (PCa): a systematic review
Authors: Jennifer Le Guévelou et al.
